Drugnews

Why did Drugnews highlight TSY-110’s route to pivotal development?

Drugnews’s October 30, 2026 analysis highlights Formosa Pharmaceuticals and EirGenix’s TSY-110, a Kadcyla biosimilar, because a European clinical trial application was filed on August 28, 2026. The article describes a March 2022 alliance worth up to US$30 million in upfront and milestone payments and a reference-product market of about US$2.5 billion in 2025 Kadcyla sales. Its pivotal-entry ranking is an editorial forecast.

Updated

TSY-110: disclosed steps and the article’s forecast
MeasureReported resultBasis
European clinical trial applicationAugust 28, 2026Application filing; not trial initiation or approval
Alliance considerationUp to US$30 millionUpfront and milestones; not all money received
Kadcyla reference-product salesAbout US$2.5 billion2025 global sales; not TSY-110 revenue
Expected first-patient announcementBy June 30, 2027Drugnews editorial forecast, not a company commitment

Formosa describes TSY-110 as an IND-enabling program with clinical initiation expected. Neither a filing nor the article’s forecast establishes that dosing has begun.

Sources

Read the full analysis

Taiwan ADCs: Who May Reach Pivotal First? — 2026-10-30